Table 2.
Course of HCV Therapy, Patient- and Clinician-Reported Outcomes—Total Sample
| Clinician-Reported | T0 | T4 | EoT | SVR12 | SVR24 |
|---|---|---|---|---|---|
| Medication adherence (n = 301–288), % | — | Very good: 90.4 Good: 9.0 Fair: 0.7 |
Very good: 86.5 Good: 13.2 Fair: 0.3 |
- | — |
| CGI-S (n = 324–256) | 3.06 (1.52) | 2.95 (1.52) | 2.91 (1.50) | 2.82 (1.51) | 2.80 (1.49) |
| CGI-I (n = 280–224) | — | 3.76 (0.64) | 3.65 (0.71) | 3.51 (0.75) | 3.46 (0.78) |
| GAF | 66.34 (17.00) | 68.14 (17.36) | 70.27 (17.39) | 71.14 (16.66) | 71.84 (16.82) |
| Medication tolerability, clinician-reported (n = 318–305), % | — | Very good: 70.1 Good: 27.0 Moderate: 2.2 Poor: 0.6 |
Very good: 70.5 Good: 24.6 Moderate: 4.9 |
— | — |
| Patient-Reported | T0 | T4 | EoT | SVR12 | SVR24 |
| Medication tolerability, patient-reported (n = 310), % | — | Very good: 53.5 Good: 39.0 Moderate: 7.1 Poor: 0.3 |
— | — | — |
| Much bothered by side effectsa | — | 3.54 (0.75) | 3.40 (0.90) | — | — |
| Feeling exhausted and weaka | — | 2.99 (1.11) | 3.03 (1.12) | — | — |
| Being sad all the timea | — | 3.47 (0.88) | 3.46 (0.90) | — | — |
| Got done less than I wanteda | — | 3.01 (1.12) | 3.04 (1.14) | — | — |
| Problems thinking straighta | — | 3.35 (0.94) | 3.32 (0.96) | — | — |
| SF-12, Physical Component Summary (n = 317–241) |
43.66 (9.32) | 44.95 (9.14) | 45.12 (9.35) | 45.44 (9.10) | 45.47 (9.05) |
| SF-12, Mental Component Summary (n = 317–241) | 42.35 (11.26) | 45.21 (11.14) | 45.35 (11.18) | 45.73 (11.35) | 45.68 (10.93) |
| MSCL, total score (GSI; n = 327–242) | 58.87 (9.32) | 56.54 (10.27) | 55.96 (11.14) | 55.41 (10.72) | 55.45 (10.87) |
| MSCL, subscale somatization (n = 327–242) | 57.69 (9.63) | 56.56 (9.69) | 56.00 (10.22) | 54.68 (10.11) | 54.94 (10.16) |
| MSCL, subscale depression (n = 327–242) | 58.16 (8.72) | 55.61 (9.62) | 55.41 (9.84) | 55.23 (9.81) | 55.38 (9.92) |
| MSCL, subscale anxiety (n = 327–242) | 57.44 (10.95) | 55.37 (11.32) | 54.89 (11.47) | 54.64 (10.80) | 54.95 (11.33) |
| OTI-HSS (n = 326–237) | 12.17 (7.62) | 11.14 (7.75) | 11.14 (8.32) | 10.14 (8.06) | 10.23 (8.13) |
| Fatigue, concentration, and memory, total scoreb (n = 325–243) | 0.79 (0.71) | 0.72 (0.77) | 0.68 (0.74) | 0.63 (0.68) | 0.66 (0.73) |
| Fatigue, concentration, and memory, subscale fatigueb (n = 325–243) | 0.93 (0.89) | 0.85 (0.94) | 0.80 (0.96) | 0.70 (0.82) | 0.72 (0.87) |
| Fatigue, concentration, and memory, subscale concentration and memoryb (n = 325–243) | 0.69 (0.71) | 0.62 (0.75) | 0.60 (0.71) | 0.58 (0.66) | 0.62 (0.70) |
Data are presented as means and standard deviations or %. Categories of clinician-rated medication adherence: “very good” (100% of the medication taken), “good” (at least 90%), “fair” (at least 80%), “poor” (<80%),
Abbreviations: CGI-I, Clinical Global Impression–improvement (ranging from 1 = “very much improved” to 7 = “very much worsened”); CGI-S, Clinical Global Impression–severity (ranging from 1 = “not at all ill” to 7 = “extremely ill”; GAF = Global Assessment of Functioning (0–100; higher scores indicate better functioning); GSI, Global Severity Index; HCV, hepatitis C virus; MCS, Mental Component Summary; MSCL, Mini Symptom Checklist, with GSI (higher scores indicate worse mental health); OTI-HSS, Opiate Treatment Index–health symptoms scale (higher scores indicate worse physical health); PCS, Physical Component Summary; SF-12, Short Form Health Assessment, consisting of PCS and MCS (higher scores indicate better quality of life).
a“Altogether, how do/did you feel during HCV treatment?” Response options: 1 = agree, 2 = rather agree, 3 = rather disagree, 4 = disagree (n = 310–287).
bHigher scores indicate higher impairments, ranging from 0 = “not at all” to 4 = “very much.”